ProShare Advisors
STRO icon

ProShare Advisors’s Sutro Biopharma STRO Stock Holding History

ProShare Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,144
Closed -$13.9K – 2179
2025
Q1 		$13.9K Sell
2,144
-552
-20% -$8.69K ﹤0.01% 2056
2024
Q4 		$49.6K Buy
2,696
+1,149
+74% +$35.1K ﹤0.01% 2177
2024
Q3 		$53.5K Sell
1,547
-85
-5% -$3.33K ﹤0.01% 1971
2024
Q2 		$47.8K Buy
1,632
+538
+49% +$21.3K ﹤0.01% 1756
2024
Q1 		$61.8K Buy
+1,094
New +$48.3K ﹤0.01% 1877
2023
Q4 		– Sell
-1,177
Closed -$40.8K – 1972
2023
Q3 		$40.8K Buy
1,177
+4
+0.3% +$174 ﹤0.01% 1730
2023
Q2 		$54.6K Buy
1,173
+140
+14% +$6.97K ﹤0.01% 1766
2023
Q1 		$47.7K Sell
1,033
-136
-12% -$8.63K ﹤0.01% 1677
2022
Q4 		$94.5K Buy
+1,169
New +$81.2K ﹤0.01% 1663
2022
Q2 		– Sell
-1,293
Closed -$105K – 2099
2022
Q1 		$105K Sell
1,293
-306
-19% -$29.1K ﹤0.01% 2021
2021
Q4 		$238K Buy
1,599
+58
+4% +$10.4K ﹤0.01% 1922
2021
Q3 		$291K Sell
1,541
-411
-21% -$78.1K ﹤0.01% 1575
2021
Q2 		$363K Buy
1,952
+461
+31% +$90.2K ﹤0.01% 1763
2021
Q1 		$339K Buy
1,491
+277
+23% +$65.7K ﹤0.01% 1722
2020
Q4 		$263K Buy
+1,214
New +$201K ﹤0.01% 1698

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

ProShare Advisors's STRO Position: Q2 2025 in Review

ProShare Advisors sold out of Sutro Biopharma (STRO) in Q2 2025, closing a stake of 2,144 shares — an estimated $13.9K sold.

ProShare Advisors first reported a position in STRO in Q4 2020 and held it in 15 quarters. The position peaked at $363K in Q2 2021. 99 funds tracked by Wall St. Rank hold STRO as of Q2 2025.

  • ProShare Advisors reported no remaining Sutro Biopharma position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 2,144 Sutro Biopharma shares in Q2 2025, an estimated $13.9K.
  • ProShare Advisors first reported a position in Sutro Biopharma in Q4 2020 and held it in 15 quarters.
  • ProShare Advisors's Sutro Biopharma position peaked at $363K in Q2 2021.
  • 99 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.